The research group consists of doctors and other health professionals at the Eye Departments of UiO and OUH. We study and treat patients with retinal diseases.
Projects
- Artificial intelligence for diagnosing retinal diseases
- The Z-AMD study: A randomized controlled pilot study of zoledronic acid as adjuvant treatment for nAMD
- The TenCRAOS study: a randomized controlled international multicenter study of trombolysis for central retinal artery occlusion
- StrokeVIS: a study of prevalence and screening for visual problems in stroke
- An evidence-based approach to the European visual requirements for driving
- Individually adjusted screening program for diabetic retinopathy by using different non-invasive measurements and symptoms
- Development of an adjustable glaucoma stent
- Intravitreal injections and the development of prefilled syringes for anti-VEGF treatment
- Endophthalmitis quality registry
- Project RP11; A collaborating study between Dept. of Microbiology and Dept. of Ophthalmology, OUH. Includes the Natural history study of autosomal dominant retinitis pigmentosa PRPF31 and TOPORS (ReSa study) investigating both clinical and pathophysiological features and progression of retinitis pigmentosa type 11 with the aim of treating the disorder
- Genotype characterization with MIP genetic testing in patients with retinitis pigmentosa and lebers congenital amaurosis
- Clinical and genetic characterization of BEST1-retinal dystrophy in South-East Norway
- PERCEIVE study; International multicenter study for post approval evaluation of the effect and safety of voretigene neparvovec
- Uveitis registry at OUH
- Registry of inherited retinal diseases in Norway
- Automatic grading of retinal images - AI
- Risk stratification in diabetic retinopathy
- The application of ultra-widefield fundus autofluorescence in the diagnosis and monitoring treatment effect of various retinal diseases and choroidal melanoma
- Characterizing the genotype, phenotype, health issues, physical functioning and quality of life in adults with Bardet Biedl syndrome
- Retinitis pigmentosa and mental health
- MaculAir study
- Incidence and survival in uveal melanoma in the Nordic countries from 1955 to 2022
- Novel prognostic and predictive markers in uveal melanoma
Cooperation
This broad range of methods requires close collaboration with research groups in Norway and abroad.
National
- Anne Hege Aamodt, Dept. of Neurology, OUH
- Jan Terje Andersen, Dept. of Immunology, UiO and OUH
-
Rigmor Baraas, Dept. of Optometry and Visual Science, Campus Kongsberg, University of South-Eastern Norway
-
Inven2, UiO
-
Elise Dees Krekling, University of South-Eastern Norway
- Charlotta von der Lippe, Dept. of Rare Disorders and Disabilities, OUH
- Jeanette Ullman Miller, Dept. of Rare Disorders and Disabilities, OUH
- Hilde Nordgarden, TAKO centre, Lovisenberg Diaconal Hospital
- Hilde Røgeberg Pedersen, University of South-Eastern Norway
- Trine Prescott, Telemark Hospital Trust
- Cecilie Rustad, Dept. of Medical Genetics, OUH
- Stephen Ryan, Dept. of Neurology, OUH
- Solrun Sigurdardottir, Dept. of Rare Disorders and Disabilities, OUH
- Erlend Sæther master student, University Hospital of North Norway
- Marie Elisabeth Vad, Dept. of Microbiology, OUH
- Susanne Weedon-Fekjær, Dept. of Rare Disorders and Disabilities, OUH
- Pamela Åsten, TAKO centre, Lovisenberg Diaconal Hospital
International
- Foundation Fighting blindness Consortium, USA
- PY Therapeutics, Australia
- Frans Cremers, Radbound University, Nijmegen, Netherlands
- Mojca Globocnik-Petrovic, Ljubljana, Slovenia
- Tomas Bro, Lund University, Sweden
- Novartis, Switzerland
- SJJ Solution, Netherlands
- Einar Stefansson, EyeRisk, Reykjavik, Iceland
- Bayer, Germany
- Roche, Switzerland